Sep 15, 2022 / 12:00PM GMT
Operator
(technical difficulty) And Communications. Mr. Wheeler, you may begin your conference.
Henry Wheeler - Innate Pharma S.A. - VP & Head of IR
Thank you very much. Good morning and good afternoon, and welcome, everybody. This morning, Innate issued a press release providing a business update for the half year '22 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website.
Please turn to Slide #2. Before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook and additional -- in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ as forecasted. Turning to Slide 3. On today's call, we will be joined by Mondher Mahjoubi, our CEO, who will then hand over to Joyson Karakunnel, EVP and Chief Medical Officer; Yannis Morel, EVP of Business
Q2 2022 Innate Pharma SA Earnings Call Transcript
Sep 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers